Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancer Research Année : 2014

Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside

Résumé

Met receptor tyrosine kinase was discovered in 1984 as an oncogene. Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising targets for the novel therapies developed to fight against cancers, with more than 240 clinical trials currently conducted. In this review, we offer to trace and highlight the most recent findings of the exemplary track record of research on Met receptor, which allowed moving this biomarker from bench to bedside. Indeed, three decades of basic research unravelled the structural basis of the ligand/receptor interaction and their complex downstream signaling network. During this period, animal models highlighted their crucial role in the development and homeostasis of epithelial organs. In parallel, involvement of Met in tumorigenesis was confirmed by the direct association of its deregulation to poor prognosis in numerous cancers. On the basis of these data, pharmaceutical companies developed many Met inhibitors, some of which are in phase III clinical trials. These impressive achievements should not detract from many questions that still remain, such as the precise Met signaling involvement in development or homeostasis of specific epithelial structures. In addition, the processes involving Met in resistance to current therapies or the appearance of resistances to Met-targeted therapies are far from being fully understood.

Domaines

Cancer

Dates et versions

hal-02413958 , version 1 (16-12-2019)

Identifiants

Citer

A. Furlan, Z. Kherrouche, R. Montagne, M.-C. Copin, D. Tulasne. Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside. Cancer Research, 2014, 74 (23), pp.6737-6744. ⟨10.1158/0008-5472.CAN-14-1932⟩. ⟨hal-02413958⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More